CLINICAL TRIALS PROFILE FOR NEURONTIN
✉ Email this page to a colleague
All Clinical Trials for NEURONTIN
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT00001482 ↗ | New Drugs in the Treatment of Mood Disorders | Completed | National Institute of Mental Health (NIMH) | Phase 2 | 1995-05-01 | This clinical study compares the effectiveness of two anticonvulsants Lamotrigine (Lamictal) Monotherapy and Gabapentin (Neurontin) in patients with treatment resistant affective disorders. We initially have found that the response rate to lamotrigine (51%) exceeded that of gabapentin (28%) or placebo (21%). In this study the placebo phase has been dropped so that we examine possible clinical and biological factors predictors of response. The drugs will be given in a randomized order for six weeks each and you will not know when you are on a given one. There will be a 2-4 week "washout" period between treatments. If you respond well to one of these treatments, a longer open continuation period will be offered at the end of this study. This would involve one or both drugs in combination. A variety of rating scales and brain imaging procedures will also be offered before and during each drug evaluation. Both lamotrigine and gabapentin are generally well tolerated. A serious potentially life threatening rash occurs in about 1/500 patients treated with lamotrigine, however. Common side effects are rash, dizziness, unsteadiness, double vision, blurred vision, nausea, vomiting, insomnia, sedation, and headache. These side effects are usually mild, and resolve with continued time on the drug or a decrease in dosage. |
| NCT00011297 ↗ | Comparing Gabapentin and Lorazepam for Treating Alcohol Withdrawal | Completed | National Institute on Alcohol Abuse and Alcoholism (NIAAA) | Phase 2 | 1969-12-31 | This study will evaluate a safe and useful medication for outpatient detoxification that is as effective as benzodiazepines in the short-term, and more effective in the protracted withdrawal period. Gabapentin (Neurontin) will be compared to a standard benzodiazepine, lorazepam (Ativan), for its effectiveness in treating alcohol withdrawal. |
| NCT00108550 ↗ | Chronic Low Back Pain Research Project | Completed | US Department of Veterans Affairs | Phase 2 | 2004-10-01 | The purpose of this study is to determine whether gabapentin is efficacious as an analgesic for chronic low back pain. |
| NCT00108550 ↗ | Chronic Low Back Pain Research Project | Completed | VA Office of Research and Development | Phase 2 | 2004-10-01 | The purpose of this study is to determine whether gabapentin is efficacious as an analgesic for chronic low back pain. |
| NCT00112138 ↗ | Gabapentin for the Treatment of Hot Flashes in Menopausal Women | Completed | North Toronto Primary Care Research Network | Phase 3 | 2004-03-01 | The purpose of this study is to evaluate the effectiveness and safety of gabapentin compared to placebo in the treatment of hot flashes in postmenopausal women using a phase III randomized controlled trial. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for NEURONTIN
Condition Name
Clinical Trial Locations for NEURONTIN
Trials by Country
Clinical Trial Progress for NEURONTIN
Clinical Trial Phase
Clinical Trial Sponsors for NEURONTIN
Sponsor Name
